Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple sclerosis drug Ocrevus. Jefferies said it downgraded the stock on three issues: anticipated modest sales of Leqembi,

Fintel reports that on December 10, 2024, Jefferies downgraded their outlook for Centene (NYSE:CNC) from Hold to Underperform. Analyst Price Forecast Suggests 41.89% Upside As of December 3, 2024, the average one-year price target for Centene is $82.

Shares of Centene (NYSE:CNC) declined 4% after Jefferies downgraded the stock to underperform from hold, citing industry headwinds over the next two years. Jefferies noted that Centene’s (CNC) membership and margins have repeatedly topped expectations over the last few years due in part to enhanced subsidies for health insurance exchange,